Abstracts tagged "Biomarkers"

Abstract Number: LB17 • ACR Convergence 2025
Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses
Sitian Zang¹, Ranran Yao¹, Yan Wang¹, Danxue Zhu¹, Jing He¹ and Zhanguo Li², ¹Peking University People's Hospital, Beijing, China (People's Republic), ²Peking Univeristy People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) features heterogeneous clinical manifestations. The identification of biomarkers that facilitate initial disease recognition is a cornerstone of optimized clinical management.…
Abstract Number: 1703 • ACR Convergence 2025
Predicting Rheumatoid Arthritis Flare Using Longitudinal Cytokine Trajectories, Machine Learning and Spatial Transcriptomic Imaging
Wittaya Suwakulsiri¹, Lukas Andriessen², Coline Fournier³, Saritha Kodikara⁴, Amy Anderson⁵, Jasmine Sim⁵, Kim-Anh Le Cao⁴, Yann Abraham⁶, Kevin Wei⁷, Kenneth Baker⁵, Arthur Pratt⁸, Mihir Wechalekar⁹, John Isaacs¹⁰ and Ranjeny Thomas¹, ¹Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ²Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, ³Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia, ⁴Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia, ⁵Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁶DeepLife, Vernon, France, ⁷Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹Flinders Medical Centre, Adelaide, Australia, ¹⁰Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Many patients living with rheumatoid arthritis (RA) can achieve remission with modern treat-to-target disease-modifying anti-rheumatic drugs (DMARDs), albeit with the risks associated with long-term…
Abstract Number: 1490 • ACR Convergence 2025
Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio
judith hernández-Sánchez¹, Beatriz Tejera Segura², Luis Bausá Gimeno¹, Doryan García Olivas¹, Patricia González Terrats¹, MA Acosta Mérida¹, Diana Botello Corzo¹, Daniel Batista perdomo¹, Sergio Machin González¹, F Javier Nóvoa Medina¹ and Jose Angel Hernandez³, ¹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, ²Hospital Insular de Gran Canaria, Las palmas, Spain, ³Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs. Vitamin D levels have been associated with disease activity in…
Abstract Number: 1220 • ACR Convergence 2025
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Wei Bian¹, Jian Hao¹, Na zhang¹, Xiaojing Zhang¹, Fumin Qi¹, Yin Zhao² and Wei Wei¹, ¹Tianjin Medical University General Hospital, Tianjin, China (People's Republic), ²Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)
Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…
Abstract Number: 0694 • ACR Convergence 2025
Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod
isabelle peene¹, Gwenny Verstappen², Joke Deprez³, Frans Kroese², Suzanne Arends², Andrew Kelly⁴, Lana Vandersarren⁵, Edward Bowen⁶, Julie Jacobs⁷, Paul Meyvisch⁸, Dirk Elewaut⁹ and Hendrika Bootsma¹⁰, ¹University Hospital Ghent, Ghent, Belgium, ²University Medical Center Groningen, Groningen, Netherlands, ³Ghent University, Ghent, Belgium, ⁴Argenx, Philadelphia, PA, ⁵Argenx, Boston, MA, ⁶IQVIA, Stevenage, United Kingdom, ⁷argenx, Ravels, Belgium, ⁸argenx, Ghent, Belgium, ⁹VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ¹⁰UMCG, Groningen, Netherlands
Background/Purpose: Background/Purpose Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration and progressive, immune-mediated dysfunction of the exocrine glands. Immunoglobulin (Ig)…
Abstract Number: 0873 • ACR Convergence 2025
Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis
Lihi Eder¹, Shangzhong Li², Philip J. Mease³, Christopher Ritchlin⁴, Walter P Maksymowych⁵, Hendrik Schulze-Koops⁶, Josef Smolen⁷, Oliver FitzGerald⁸, Vinod Chandran⁹, Chun Wu¹⁰ and Jinqi Liu², ¹University of Toronto, Toronto, ON, Canada, ²Bristol Myers Squibb, Princeton, NJ, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Rochester Medical Center, Canandaigua, NY, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, ⁷Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁸UCD, Dublin ⁶, Dublin, Ireland, ⁹Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ¹⁰Bristol Myers Squibb, Princeton
Background/Purpose: PsA affects male and female patients equally; however, variations in manifestations and treatment response exist between sexes. Deucravacitinib is an oral, selective, allosteric tyrosine…
Abstract Number: 0758 • ACR Convergence 2025
Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis
Raquel Ugena-García¹, Clara Churtichaga Domenech², Judith Vidal-Ripoll², Francina salabert-Carreras², Cristina Calomarde-Gómez¹, Cristina Rocamora-Gisbert³, Irene Peralta-García⁴, Niccolo Viveros², Anne Riveros Frutos³, Ivette Casafont-Solé¹ and Judit Font-Urgelles¹, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, ³Hospital Germans Trias i Pujol, Barcelona, Spain, ⁴Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in patients over the age of 50. Interleukin-6 (IL-6) has been shown to…
Abstract Number: 0406 • ACR Convergence 2025
Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Mariia Pavlenko², Mekibib Altaye³, Hermine Brunner⁴, Margaret Chang⁵, Ashley Cooper⁶, Stefanie Davidson⁷, Alexandra Duell⁴, Bharti Gangwani⁵, Aimee Hersh⁸, Gary Holland⁹, Carl Langefeld¹⁰, Melissa Lerman¹¹, Mindy Lo⁵, Virginia Miraldi Utz⁴, Sampath Prahalad¹², Grant Schulert⁴, Megan Quinlan-Waters¹³, Erin Stahl⁶, Edmund Tsui⁹ and Sheila Angeles-Han¹⁴, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, ³Cincinnati Children's Hospital, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Boston Children's Hospital, Boston, MA, ⁶Children's Mercy Kansas City, Kansas City, MO, ⁷Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, ⁸University of Utah, Salt Lake City, UT, ⁹UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, ¹⁰Wake Forest University School of Medicine, Winston Salem, NC, ¹¹Children's Hospital of Philadelphia, Philadelphia, PA, ¹²Emory + Children's Pediatric Institute, Atlanta, GA, ¹³Cincinnati Children's Hospital Medical Center, CCHMC, ¹⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Chronic anterior uveitis (CAU) develops in 15-20% of juvenile idiopathic arthritis (JIA) cases. Early detection may prevent vision loss. However, known clinical risk factors…
Abstract Number: 0094 • ACR Convergence 2025
Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs
Sagrario Corrales¹, Laura muñoz-Barrera¹, Rafaela Ortega-Castro², Elena Moreno-Caño³, Jerusalén Calvo⁴, Concepción Aranda-Valera⁴, Lourdes Ladehesa⁵, Pilar Font⁶, Ismael Sanchez-Pareja¹, M Carmen Abalos-Aguilera⁷, Desiree Ruiz-Vilchez⁸, Christian Merlo⁹, MARIA ANGELES AGUIRRE ZAMORANO¹, Tomás Cerdó¹, Nuria Barbarroja¹⁰, Marta Alarcon-Riquelme¹¹, Alejandro Escudero Contreras⁴, Carlos Pérez Sánchez¹² and Chary López pedrera¹³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁴IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁸Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ⁹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 20–40% of patients do not respond to biologic or targeted synthetic DMARDs (b/tsDMARDs). Understanding each drug’s molecular…
Abstract Number: 2589 • ACR Convergence 2025
Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome
Yuanpiao Ni¹, Fanxin Zeng², Yufeng Qing³ and Quanbo Zhang³, ¹Affiliated Hospital Of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic), ²Dazhou Central Hospital, Dazhou, Sichuan, China (People's Republic), ³The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic)

Background/Purpose: Gout is a metabolic disorder driven by abnormalities in urate metabolism and chronic inflammation. Recent studies suggest that gout is not limited to joint…
Abstract Number: 2335 • ACR Convergence 2025
The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain.
Walter P. Maksymowych¹, Raj Sengupta², Anthony Marotta³, Stephanie Wichuk⁴, Charlotte Cavill⁵, Stephen Bleakley³ and Norma Biln⁶, ¹Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ²Royal National Hospital for Rheumatic Diseases, Bath, England, United Kingdom, ³Augurex Life Sciences Corp, Vancouver, BC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Royal United Hospitals Bath NHS Foundation Trust, Bath, England, United Kingdom, ⁶Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: Reducing diagnostic delay for people presenting with back pain who have axial spondyloarthritis (axSpA) has become a clinical imperative since effective treatments can limit…
Abstract Number: 2085 • ACR Convergence 2025
Estimating the Association between Effusion-synovitis and Knee Pain in a Subset of Participants with Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)
Dagoberto Robles¹, Greg Gilles², Nathaniel H. Christiansen³, Luke Grawer⁴, Karim Jayyusi⁴, Ali Shaikh⁴, Rongrong Tang⁵, Mihra S. Taljanovic⁴, Jeffrey Duryea⁶, Edward J. Bedrick⁵ and C. Kent Kwoh⁷, ¹University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, The University of Arizona College of Medicine, Tucson, AZ, ³University of Arizona, Stockton, NJ, ⁴University of Arizona, Tucson, ⁵The University of Arizona Arthritis Center, University of Arizona, Tucson, ⁶Brigham and Women’s Hospital, Boston, MA, ⁷The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ
Background/Purpose: Even though knee pain is ubiquitous in knee osteoarthritis (KOA) patients, currently there are limited treatment options which are only minimally or moderately efficacious…
Abstract Number: 1834 • ACR Convergence 2025
Integrative Bioinformatics Analysis Reveals Key Genes and Immune Profiles Associated with Preeclampsia in Lupus Pregnancy
Rodolfo Martinez-Canales¹, Eva Abigaid Galindo-Calvillo², Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³, Cassandra Michele Skinner-Taylor², Mario Cesar Salinas-Carmona¹ and Noe Macias-Segura¹, ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Preeclampsia (PE) is a serious complication of pregnancy associated with significant maternal and fetal outcomes. Systemic lupus erythematosus (SLE) significantly increases the risk of…
Abstract Number: 1702 • ACR Convergence 2025
Powerful and Accurate Case-Control Analysis of Spatially Resolved Molecular Data in Autoimmune Disease
Yakir Reshef¹, Lakshay Sood¹, Michelle Curtis¹, Laurie Rumker², DANIEL STEIN³, Mukta Palshikar¹, Saba Nayar⁴, Andrew Filer⁵, Anna Helena Jonsson⁶, ilya Korsunsky⁷ and Soumya Raychaudhuri⁷, ¹Brigham and Women's Hospital, Boston, ²Broad Institute, Boston, ³Harvard University, Boston, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵The University of Birmingham, Birmingham, United Kingdom, ⁶University of Colorado School of Medicine, Aurora, CO, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) involve complex spatial organization of immune and stromal cells within inflamed tissues. As spatial molecular profiling methods…
Abstract Number: 1480 • ACR Convergence 2025
Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
CHEN-YU LEE¹, Rufei Lu², Carla Guthridge², Wade DeJager³, Jennifer Barnas⁴, Jennifer Anolik⁵, H Michael Belmont⁶, Judith James², Jill Buyon⁷, Brad Rovin⁸, Michelle Petri⁹, Joel Guthridge² and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴University of Rochester, Rochester, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸The Ohio State University, Columbus, OH, ⁹Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Early treatment is critical to prevent irreversible kidney damage in lupus nephritis (LN). Current guidelines recommend kidney biopsy when the urine protein-to-creatinine ratio (UPCR)…

1
2
3
…
109
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].